Ulcerative Colitis Symptoms While in Remission

If you have been told you are in remission and you are still getting urgency, soft stools, cramping or fatigue, the most useful thing to know is this: "remission" almost never means "back to the bowel you had before diagnosis". It means inflammation is controlled by whichever measure your team checked. Those are different claims, and the gap between them is where most of this confusion lives. If fatigue is the main one, check iron first: our guide to ulcerative colitis fatigue and low iron explains why a colon disease can drain it.

The second thing to know is that lingering symptoms are not automatically something to accept. Research repeatedly finds that when people in apparent remission report ongoing gut symptoms, a meaningful share of them still have low-level inflammation nobody has retested for. So the honest answer to "is this just my new normal?" is: possibly, but that should be a conclusion you reach after a test, not before one.

This guide separates the five things "remission" can mean, walks through what the evidence says about symptoms that persist anyway, and gives you a way to put it to your IBD team that gets something measured.

The short answer: which remission did they mean?

When a gastroenterologist says "you are in remission", they are making a specific claim about a specific measurement, and there are at least four measurements in common use.

The international consensus that shapes most IBD care, STRIDE-II, sets out the targets explicitly. Symptomatic relief and normalisation of blood and stool markers are treated as short-term targets. Clinical remission and endoscopic healing are the long-term targets. Histological healing in ulcerative colitis is not a formal target, but the consensus says it should be assessed as a measure of the depth of remission (Turner 2021).

Stacked up, they look like this.

Three practical consequences follow.

First, someone can be in one kind of remission and not another, and the word used in your letter may not be the one you assumed. Second, the rungs disagree. Symptom scores and endoscopy come apart in both directions, which is the subject of most of the rest of this article. Third, none of these four rungs is "back to normal". That is a fifth thing, and no guideline promises it.

A post in r/UlcerativeColitis from someone a year into a proctitis diagnosis put the question in the plainest possible terms: is remission supposed to be completely normal bowel movements and no cramps like everyone else, or is it more like better most of the time but not perfect (r/UlcerativeColitis thread). The replies split down the middle, with some saying remission means your old normal unless you have permanent damage, and others describing years of remission with rarely normal stools. Both camps are describing something real. They are answering different questions.

How common is this, in numbers?

Common enough that it should be a routine part of the consultation rather than a surprise.

The best single estimate comes from a systematic review and meta-analysis of 27 studies covering 3,169 adults with IBD in remission. Pooled prevalence of symptoms meeting diagnostic criteria for IBS was 32.5% (95% CI 27.4 to 37.9). Broken down by condition it was 28.7% in ulcerative colitis and 36.6% in Crohn's disease. Broken down by how remission was defined, it was 33.6% when remission came from a clinical activity index and 23.5% when remission was confirmed at endoscopy (Fairbrass 2020).

One detail in that paper is worth printing rather than smoothing over. The subgroup where remission was defined histologically, the strictest definition of the four, came out at 25.8%, which is higher than the endoscopic figure of 23.5%. If deeper remission straightforwardly meant fewer symptoms, you would expect the opposite order. The paper reports the heterogeneity statistic for that histological subgroup as "not applicable", which in practice means it rests on a single study rather than a pooled set. So the 25.8% is a single estimate sitting next to a pooled one, and the apparent ordering is not something the data can support either way. It is a reminder that "stricter definition" and "fewer symptoms" are not the same axis.

Why stool frequency stays up after the bleeding stops

Because bleeding and stool frequency are not equally good at tracking inflammation, and stool frequency picks up things that have nothing to do with it.

The clearest demonstration comes from an observational study of 103 people with ulcerative colitis, which compared the rectal bleeding and stool frequency items of the Mayo score against endoscopy and histology. Across three increasingly strict definitions of mucosal healing, the proportion still reporting increased stool frequency was 39%, 25% and 27%. The proportion still reporting rectal bleeding was 24%, 13% and 10% (Colombel 2017).

Read that again, because it is the single most useful pair of numbers in this article. Absence of bleeding was a reasonably good sign that the lining had healed. Normal stool frequency was not. Roughly a quarter of people with a healed lining still went more often than they used to.

The authors' own interpretation was that non-inflammatory changes, such as long-term bowel damage, may keep stool frequency up after inflammation settles. That is a structural explanation, not a psychological one.

The same paper also found something that cuts against a common hope. Achieving histological remission did not improve symptomatic relief, and inflammatory biomarkers were no lower in the histological remission group than in the endoscopic one (Colombel 2017). If you have been told that pushing for deeper remission will resolve the leftover symptoms, this study is the reason to ask how confident anyone is about that.

That is not an argument against deep remission. Histological remission does predict a longer relapse-free period: in a cohort of 74 people with UC in clinical and endoscopic remission, histological activity on the Nancy index was the only independent risk factor for later clinical relapse on multivariate analysis, with a hazard ratio of 4.36 (Wang 2023). A separate prospective study of 187 people using the Robarts index found the same direction, with histological remission independently associated with lower relapse risk (Park 2022). And in the upadacitinib maintenance programme, people reaching combined histological and endoscopic remission had better odds of most long-term outcomes, although the paper notes that for most patient-reported outcomes the difference between histological-plus-endoscopic remission and endoscopic improvement alone was not statistically significant (Parkes 2023). That trial was a manufacturer-run phase 3 programme and several authors declare consulting relationships with the sponsor and other IBD drug companies.

So the honest framing is: deeper remission buys you a lower chance of your next flare. It does not buy you a guaranteed normal week.

The rectum takes longer to recover than the lining

Urgency, tenesmus and the feeling of never quite emptying are generated largely in the rectum, and rectal mechanics do not reset the moment the ulcers close. Our dedicated guide to tenesmus in ulcerative colitis takes that symptom on its own, including the problem that no standard activity score contains it.

A prospective study measured anorectal function in 36 people with active ulcerative colitis and 10 healthy volunteers, using high-resolution anorectal manometry and a rectal barostat, once during active disease and again four to six months after starting treatment. During active disease, faecal incontinence, urgency and tenesmus were reported by 66.7%, 91.7% and 83.3%. After treatment, symptoms improved, but a substantial group stayed symptomatic: 32.3% still reported incontinence, 54.8% urgency and 51.6% tenesmus. Greater endoscopic and histological activity correlated with lower sensory thresholds and reduced rectal capacity and compliance. Crucially, barostat measurements remained abnormal after treatment compared with healthy controls, including in people who had reached histological remission (Martínez 2026).

Those percentages work out to ten, seventeen and sixteen people out of the thirty-one who had repeat testing, so this is a small study, and it was funded by two Spanish gastroenterology societies rather than industry.

A third study adds a variable that may explain part of the split. In 33 people with recurrent ulcerative colitis compared against 40 newly diagnosed patients, long disease duration and high faecal calprotectin were independent determinants of a lower initial sensation threshold, and calprotectin was also independently associated with the defecation volume and urgency thresholds. Anxiety score was independently associated with the defecation volume threshold (Wu 2024). In other words, how long you have had colitis and how much inflammation is still there both shape how sensitive your rectum is.

If urgency is your main leftover symptom, this is the physiology behind it, and our post on how to stop urgency with ulcerative colitis goes through what actually reduces it and what the trial evidence supports. Urgency also has a measurement problem of its own: a 2026 review of the patient-reported tools used to capture it in UC found five that met formal regulatory standards, and concluded that some dimensions of urgency are missing from all of them (Dubinsky 2026). It is worth knowing that most of the literature defining and measuring urgency in UC has been produced alongside drug development programmes, which is why it is a good idea to describe your own urgency in your own terms as well as any number.

Is it really remission? The occult inflammation question

This is the possibility to rule out first, because the evidence says it explains a large share of cases.

A prospective study assessed 62 people with Crohn's disease and 44 with ulcerative colitis, all judged to be in remission by physician assessment plus a normal CRP and off steroids and biologics. Rome II criteria for IBS were met by 59.7% of the Crohn's group and 38.6% of the UC group. But faecal calprotectin was significantly raised above the upper limit of normal in both groups, and calprotectin was significantly higher in those meeting IBS criteria than in those who were not (Keohane 2010). The authors' conclusion was blunt: the mechanism in most cases is likely to be occult inflammation rather than a coexisting irritable bowel syndrome.

A later study using caecal biopsies found a mechanism consistent with that. Comparing 51 people with IBS, 49 with quiescent IBD and 27 controls, it found that people with quiescent IBD who had IBS-like symptoms had significantly increased paracellular permeability and lower expression of the tight junction proteins ZO-1 and alpha-catenin, plus significantly increased intraepithelial lymphocytes and TNF-alpha, compared with quiescent IBD patients without those symptoms. Notably, the lymphocyte and TNF-alpha increases were seen in quiescent IBD with symptoms but not in the IBS group, which is evidence that these two look-alike situations are not the same thing underneath (Vivinus-Nébot 2014).

The practical version: if you feel bad in "remission", the first question is not "how do I cope with my new normal", it is "when was my inflammation last actually measured". Our guide to what calprotectin levels mean in ulcerative colitis covers how to read the number you get back, including why one sample is a noisy sample.

What the guidelines say to do about it

Both major American guidelines address this situation directly, and they do not say to wait.

The AGA guideline on biomarkers suggests that people with UC in symptomatic remission be monitored with a biomarker-and-symptom strategy rather than symptoms alone, and suggests using faecal calprotectin under 150 micrograms per gram, normal faecal lactoferrin and/or normal CRP to rule out active inflammation and avoid routine endoscopy. It then addresses your exact situation: for people in symptomatic remission but with raised biomarkers, and for people with moderate to severe symptoms but normal biomarkers, the panel suggests endoscopic assessment to inform treatment decisions. For people with mild symptoms, it also suggests endoscopic assessment (Singh 2023).

That is worth spelling out because it inverts a common assumption. A normal calprotectin when you have real symptoms is not the end of the investigation under this guideline. It is a reason to look.

The ACG guideline update similarly recommends faecal calprotectin for evaluating suspected relapse, noting it is more sensitive and specific than blood markers and less invasive than colonoscopy (Rubin 2025).

Everything else that can cause gut symptoms when colitis is quiet

Once inflammation has genuinely been ruled out, there is a real list, and most of it is checkable.

Constipation in the colon above the inflamed segment. This has a name in the literature: ulcerative colitis-associated constipation syndrome, or proximal constipation. In a cross-sectional series of 125 people with UC, 58 (46%) met a working definition of it. The main features were reduced stool frequency (69%), hard stools (43%), abdominal pain (40%), excessive flatus (29%), straining (24%) and a sensation of incomplete emptying (14%). It was associated with female sex, left-sided disease and concurrently active disease (James 2018). That last association matters: it was commoner when disease was active, so finding it is not a reason to skip checking inflammation.

Lactose. Worth testing rather than assuming. In 54 people with IBD in clinical remission compared with 69 matched controls, hydrogen breath tests were positive in 64.8% of the IBD group and 62.3% of controls, with no significant difference, and the distribution of lactase gene variants was also similar. The authors' point was that roughly a third of IBD patients with suggestive symptoms are not lactose intolerant at all, so an automatic dairy elimination is not justified (Nardone 2021). This was an Italian population, where lactase non-persistence is common, so the raw percentages will not transfer everywhere.

Small intestinal bacterial overgrowth. A meta-analysis of 11 studies, 1,175 adults with IBD and 407 controls, all using breath testing, found SIBO in 22.3% of people with IBD, with an odds ratio versus controls of 9.51, and 7.96 specifically for ulcerative colitis (Shah 2019). A larger, later meta-analysis of 29 studies put the pooled prevalence at 31.0%, with 27.8% in UC (Feng 2024). Breath testing is a contested tool with a shaky evidence base of its own, which we go through in SIBO versus IBS symptoms, so treat these numbers as "worth a conversation", not as a diagnosis.

Bile acid malabsorption. This is mostly a Crohn's problem rather than a UC one, and it is worth being clear about that. In a study of 347 people with IBD and 119 controls using serum C4 and FGF19, the most severe bile acid malabsorption was in people with Crohn's disease after resection of the distal ileum, though it was also present in 14% of non-operated patients with ileitis and 11% with Crohn's colitis (Lenicek 2011). Those subgroup figures are Crohn's disease, not ulcerative colitis. It becomes relevant in UC mainly after a colectomy with a pouch or an ileorectal anastomosis, where the anatomy has changed.

Fermentable carbohydrates. A single-blind randomised trial in 52 people with quiescent Crohn's disease or ulcerative colitis and persistent gut symptoms compared four weeks of a low FODMAP diet against a control diet. Adequate relief of gut symptoms was reported by 52% on the low FODMAP diet versus 16% on the control diet (p=.007). But the reduction in IBS severity score, the trial's continuous symptom measure, was not statistically significantly different between groups (p=.075), and the low FODMAP group ended the study with significantly lower abundance of several beneficial gut bacteria, including Faecalibacterium prausnitzii (Cox 2020). Low FODMAP is a short, structured process with a planned reintroduction phase, best done with a dietitian, and never a permanent diet. There is more on how it applies in colitis specifically in is a low FODMAP diet good for ulcerative colitis.

Continence, which people rarely raise. In a cross-sectional survey of 392 people attending IBD clinics in Switzerland, 116 (29.5%) reported faecal incontinence in the previous four weeks. It was associated with age over 50, vaginal delivery, disease duration over 15 years, and with markers of activity including an SCCAI of 3 or more (odds ratio 6.06) (Hammond 2025). That was published in Cureus, a journal with a light peer review process, so weigh it accordingly, and note that the strongest association was with disease activity, which again points back at testing first.

Infections and medication. A new gut infection or a medication side effect can produce symptoms in someone whose colitis is quiet. Neither is something to work out yourself. If symptoms are new, different or accelerating, that is a call to your IBD team, not a change you make at home.

Fatigue in remission is not a failure of willpower

It is one of the most reported leftover symptoms, and the evidence says it does not track neatly with how deep your remission is.

In the IBSEN III cohort, 711 people with Crohn's disease or ulcerative colitis were assessed one year after diagnosis, with remission split into symptomatic, biochemical, endoscopic or radiological, and histological. Symptomatic remission significantly reduced the odds of substantial and chronic fatigue for both conditions, and biochemical remission reduced the odds of substantial fatigue in UC. But the paper's own conclusion is the important line: stricter definitions of disease remission were not associated with a decreased likelihood of fatigue. Among the 181 people in endoscopic or radiological remission, chronic fatigue was independently associated with sleep disturbance (OR 10.40) and with current infliximab treatment (OR 4.31) (Holten 2025).

The infliximab association is an observational finding in a cohort, not evidence that the drug causes fatigue, and people on infliximab differ systematically from people not on it. It is a reason to mention fatigue at your infusion appointments, not a reason to change anything.

An older study found that fatigue and disease-related worries clustered with IBS-type symptoms: among 89 IBD outpatients in remission, fatigue questionnaire scores were significantly elevated in the UC patients who met IBS criteria (Jelsness-Jørgensen 2012).

Iron is the thing most people want checked, and the evidence is genuinely mixed. A systematic review found seven eligible studies covering 1,425 people, with variation in methods so great that no quantitative synthesis was possible. Its conclusion was that two studies found evidence of a slight increase in fatigue in people with iron deficiency without anaemia, which does not explain all fatigue in IBD (Sartain 2025). I should flag an oddity: the abstract's results paragraph says two studies showed people with iron deficiency without anaemia had "significantly lower fatigue scores", while the conclusion describes a slight increase in fatigue in the same group. That is consistent only if the instruments score lower as fatigue worsens, which is true of some scales but is not stated in the abstract, and I could not resolve it without the full text. Read the direction of that finding with caution. One of the senior authors declares extensive consultancy and research funding from pharmaceutical companies including two iron manufacturers, and the work was supported in part by a research agreement with a nutrition company.

Fatigue in IBD is a large enough topic that we treated it separately in Crohn's fatigue in remission, and most of what is in there about sleep, mood, deconditioning and how to describe it applies just as much to ulcerative colitis.

Mood is part of the picture, and that is not a dismissal

Saying anxiety is involved is not the same as saying the symptoms are imaginary. The evidence runs in both directions, which is exactly why it is not a diagnosis of exclusion.

A meta-analysis of 77 studies and 30,118 people with IBD found pooled prevalence of anxiety symptoms of 32.1% and depression symptoms of 25.2% (Barberio 2021). A two-year prospective study of 405 people found the arrow pointing both ways: baseline disease activity was associated with an almost six-fold increased risk of a later abnormal anxiety score (HR 5.77), and among people whose IBD was quiescent at baseline, abnormal anxiety scores predicted later flare or need for steroids (HR 2.08) (Gracie 2018). A meta-analysis of 12 longitudinal studies and 9,192 patients found the same bidirectionality at scale (Fairbrass 2022).

A review of the field is honest about what this does and does not buy you in treatment. In IBS, treatments aimed at the brain-gut axis improve symptoms and quality of life. In IBD, the benefit is less certain, mainly because there have been few interventional studies (Gracie 2019).

One recent analysis is worth knowing about because of what it did not find. In a latent profile analysis of baseline data from 780 people in a trial of a digital symptom intervention, three symptom profiles emerged: moderate (50%), high (40%) and severe (10%). Diagnosis and faecal calprotectin were not associated with which profile someone fell into. Depression, anxiety, negative symptom perceptions and all-or-nothing and avoidance behaviours were (Wileman 2025). The authors note plainly that many participants had symptoms even when deemed to be in clinical remission. Two of the authors declare an interest in a commercial digital CBT product for IBS, one through a licence agreement between their university and the company, which is relevant context for a paper arguing that cognitive behavioural factors matter.

There is a real tension between this paper and the Keohane findings above: one says calprotectin explains the symptom burden, the other says it does not predict which symptom cluster you land in. They are measuring different things, a continuous biomarker against a categorical profile, but they pull in different directions and both deserve to be on the table.

What "normal" bowel movements actually look like

The comparison most people are making is to an idealised normal that most of the population does not have either.

The reference data still comes from a survey of 1,897 adults in East Bristol, 72.2% of a random stratified sample, most of whom recorded three consecutive defecations and rated stool form on a validated scale. Once daily was the most common habit but was a minority practice in both sexes. A regular 24-hour cycle was apparent in only 40% of men and 33% of women. A third of women went less often than daily. And stool types classed as normal, meaning those least likely to evoke symptoms, accounted for only 56% of all stools in women and 61% in men (Heaton 1992).

The authors' own conclusion was that conventionally normal bowel function is enjoyed by less than half the population.

This is why a thread in r/IBD asking people in remission whether they have "firm, solid, banana-shaped" stools produced answers that read as disappointing but are largely within the range of ordinary human variation (r/IBD thread). Several people described going once or twice a day with stool that varies in consistency and only occasionally hits the textbook shape. That is not a failing of their remission.

What is not ordinary variation, and what should be reported: blood, night-time waking to open your bowels, a change in your own usual pattern that persists, urgency that stops you leaving the house, and weight loss.

A worked example: two people, both told they are in remission

Both get the same sentence in clinic. They need different next steps.

Person A. Left-sided colitis, diagnosed three years ago, last colonoscopy eight months ago showing a Mayo endoscopic subscore of 0. No bleeding for over a year. Opens bowels twice a day, stool usually soft but formed, occasional cramping after large meals, no night-time symptoms, no urgency, weight stable, energy roughly back to baseline. Their pattern has been stable for six months.

This looks like the situation the Colombel data describes: healed lining, stool frequency that has not returned to the pre-diagnosis baseline. A calprotectin is still reasonable for reassurance, but if it is normal and nothing is changing, the conversation is about living with a slightly altered baseline, not about escalating anything.

Person B. Extensive colitis, last scope fourteen months ago, no visible blood, but urgency most days, two episodes of not making it to the toilet in the past month, waking once or twice a night, stool consistently loose, and increasing fatigue over eight weeks. They were told at their last phone appointment that it would settle.

Nothing about that is a stable new normal. There is a trend, there is night-time waking, there is urgency affecting daily life, and the last objective measurement is over a year old. Under the AGA guideline, a calprotectin now, and endoscopic assessment if symptoms are moderate to severe even when the biomarker comes back normal, is the recommended path (Singh 2023). The distinguishing features are not the absolute symptoms, they are the trend, the night-time symptoms, and the age of the last objective test.

A thread in r/UlcerativeColitis from someone in almost exactly Person B's position, told by their GI that horrible urgency and accidents would pass, drew a strong response from the community arguing that a quality-of-life problem of that size should not be dismissed (r/UlcerativeColitis thread). The community was right that it warranted more than reassurance, and the evidence above explains why: urgency is both a plausible consequence of lasting rectal changes and a plausible sign of inflammation nobody has looked for recently.

What to track so the next appointment goes differently

Vague reports get vague answers. Three numbers and a date beat a paragraph of adjectives.

1. Stool frequency per day, and how many are urgent. The urgent count is the one that most often gets left out, because it is not in PRO-2 and often not asked. Our post on the PRO-2 score in ulcerative colitis explains what that two-item score does and does not capture.
2. Bleeding, yes or no, by day. This is the item that tracks the lining best, per the Colombel data, so an accurate record of it carries real weight.
3. Night-time waking to open your bowels. A binary yes or no per night. It is one of the clearest dividing lines between a functional pattern and an inflammatory one.
4. A stability question. Is this the same as last month, better or worse? Trends are what change clinical decisions.
5. The date of your last calprotectin, CRP and colonoscopy. Bring these. Half the argument in these appointments is about how old the last objective test is.

Six to eight weeks of that fits on a page. If you already log meals, keep them in the same place, but do not let food hunting crowd out the four items above, because the decision your team is making is about inflammation, not ingredients.

This is the kind of record Clairop is built to produce: logging takes seconds, and the app generates a one-page report for a GI visit with your activity score, bowel pattern, medication adherence and labs on it, which is far easier to hand over than a fourteen-month scroll.

How to say it so it is heard

The framing that tends to work is impact plus measurement plus a question, rather than a description of how bad it feels.

Try: "Since June I have had urgency on most days, I have had two accidents this month, and I am waking at night twice a week. My last calprotectin was in March. Can we repeat it, and can we talk about what happens if it comes back normal?"

Compare with: "I still don't feel right." The second is true and it is the harder one to act on.

If you are being brushed off repeatedly, that is a systemic problem rather than a personal one, and there are proper escalation routes. Our guide to getting your doctor to take you seriously covers second opinions, changing practice and formal advocacy routes, and most of it transfers directly to IBD care.

Dangerous shortcuts that show up in the threads

Myths about symptoms in remission

"If you have symptoms, you are not in remission." This is a common reply in the threads, and it is a defensible use of the word but not the clinical one. Under the STRIDE-II framework, remission is defined against specific targets, and symptom resolution is one target among several (Turner 2021). Insisting on the strict version is unhelpful when it makes people feel their remission is fake. Insisting on the loose version is unhelpful when it makes people accept untested symptoms. The way out is to ask which measurement was taken and when.

"Push for histological remission and the symptoms will go." The 103-patient study found histological remission did not improve symptomatic relief (Colombel 2017). Pursue it for the relapse-risk benefit shown by Wang 2023 and Park 2022, not as a symptom fix.

"Cannabis puts UC into remission." The trial evidence does not support this, and one of the trials went the other way. In a randomised, double-blind, placebo-controlled trial of 32 people with mild to moderately active UC, THC-rich cannabis cigarettes improved the Lichtiger clinical index and quality of life significantly more than placebo, but the change in Mayo endoscopic score was not significantly different between groups (p=0.17), and laboratory inflammatory markers did not improve (Naftali 2021). One of that paper's authors is an employee of the cannabis company that supplied the study product, which is disclosed in the paper. A review of the randomised evidence across five trials and 185 participants was blunter: in a 60-person UC trial, 24% of the cannabis oil group reached clinical remission versus 26% of the placebo group, a numerically worse result in the treated arm, and adverse events were more prevalent in the cannabis groups in both Crohn's and UC studies. The review concluded that no firm conclusions can be made about safety or effectiveness (Kafil 2020). Whatever cannabis is doing in the trials that showed a clinical benefit, it is not visibly reducing inflammation, and that matters when the alternative on offer is a treatment that does.

"People have completely recovered from ulcerative colitis." This appears in the threads, and it is not how the condition behaves. Ulcerative colitis is a relapsing and remitting condition, and the treatment target frameworks are built entirely around maintaining remission rather than ending the disease (Turner 2021). Long, deep remission is a genuine and common outcome. Cure is a different claim and nothing in the guidelines supports it.

"IBS-type symptoms in remission mean you have picked up IBS as well." Sometimes, but the evidence says treat that as a conclusion of last resort. Calprotectin was significantly higher in the people with those symptoms in the Keohane study, and the biopsy study found immune changes in quiescent IBD with symptoms that were absent in IBS (Keohane 2010, Vivinus-Nébot 2014).

"Fatigue means a flare is coming." Sometimes, but the IBSEN III data found fatigue persisted regardless of how strictly remission was defined, and the strongest association in people in endoscopic remission was with sleep disturbance (Holten 2025). Report it, get it looked at, but do not read every tired week as an impending relapse. Our post on how to tell if your ulcerative colitis is flaring goes through which signals carry the most information.

When to see a doctor promptly

Contact your IBD team promptly if any of these appear or return:

• Blood in your stool, new or increasing, at any volume
• Unexplained weight loss
• Fever, or feeling systemically unwell
• Night-time symptoms: waking from sleep to open your bowels, or night sweats
• Symptoms of anaemia: breathlessness on stairs, unusual pallor, a racing heart, new dizziness
• A persistent change from your own usual pattern lasting more than a week or two
• Severe or worsening abdominal pain, particularly with vomiting or abdominal swelling
• Urgency or incontinence that is affecting your daily life, which is a quality-of-life issue worth escalating in its own right
• New symptoms outside the gut, such as joint pain, eye pain or redness, or a new skin rash
• Symptoms starting after age 50, a family history of bowel cancer, or any new alarm feature, all of which deserve prompt assessment regardless of your colitis

None of those is a reason to panic. All of them are reasons to make contact rather than wait for your next scheduled appointment.

The honest bottom line

Being told you are in remission and still having symptoms is one of the most common experiences in ulcerative colitis, reported by roughly a quarter to a third of people depending on how remission was defined (Fairbrass 2020). It is not unusual, and it is not you failing at remission.

The order of operations matters more than any single explanation:

1. Find out which remission you were told you were in, and when it was measured. If the answer is "a symptom score, fourteen months ago", that is the problem to solve first.
2. Rule out leftover inflammation before accepting a functional explanation. The prospective evidence says occult inflammation is the likeliest single cause, and a normal calprotectin with real symptoms is a reason for endoscopic assessment under the AGA guideline, not a reason to stop looking (Keohane 2010, Singh 2023).
3. Expect stool frequency to be the slowest thing to come back. Bleeding tracks the lining well, stool frequency does not, and roughly a quarter of people with a healed lining still go more often than they used to (Colombel 2017).
4. Do not let anyone promise that deeper remission will fix how you feel. It lowers your relapse risk. In the study that looked, it did not improve symptom relief.
5. Treat urgency as a symptom that gets measured, not waited out. Rectal sensitivity and compliance can stay abnormal for months after treatment in some people and recover in others, and the two studies that looked disagree, so nobody can honestly tell you which you are (Martínez 2026, Gravina 2022).
6. Be sceptical of anything that improves how you feel without touching inflammation. That is the specific pattern the cannabis trials showed, and in the larger UC trial the cannabis arm did numerically worse than placebo on clinical remission, with more adverse events (Naftali 2021, Kafil 2020).

And if, after all of that, the answer really is that your baseline has shifted, that is worth naming out loud rather than quietly failing to reach a standard nobody set. Less than half the general population has what the textbooks call normal bowel function anyway (Heaton 1992). A stable, predictable, bleeding-free pattern that is not quite what you had at twenty-two is a good outcome, and it is a different thing from an unchecked symptom you were told to sit with.